AstraZeneca (AZN) Reports Results from Positive Ph. III THEMIS Trial Showing BRILINTA Reduced Risk of Cardiovascular Events
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) today announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA (ticagrelor) plus aspirin ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
